Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

BCR/ABL and chromosomal instability: debate resolved.

Carroll M.

Blood. 2012 Jun 28;119(26):6180-1. doi: 10.1182/blood-2012-05-423897. No abstract available.

2.

Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3.

Liu LG, Tanaka H, Ito K, Kyo T, Ito T, Kimura A.

Am J Hematol. 2003 Dec;74(4):268-72. Review.

3.

[Cancer initiation as mini-evolution].

Iwasa Y.

Tanpakushitsu Kakusan Koso. 2005 Dec;50(15):1962-9. Review. Japanese. No abstract available.

PMID:
16363646
4.

Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia.

Barnes DJ, Melo JV.

Acta Haematol. 2002;108(4):180-202. Review.

PMID:
12432215
5.

A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia.

Jørgensen HG, Holyoake TL.

Hematol Oncol. 2001 Sep;19(3):89-106. Review.

PMID:
11574931
6.

Stem cell biomarkers in chronic myeloid leukemia.

Jiang X, Zhao Y, Forrest D, Smith C, Eaves A, Eaves C.

Dis Markers. 2008;24(4-5):201-16. Review.

7.

Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.

Drexler HG, MacLeod RA, Uphoff CC.

Leuk Res. 1999 Mar;23(3):207-15. Review.

PMID:
10071072
8.

Molecular biology of chronic myeloid leukemia.

Maru Y.

Int J Hematol. 2001 Apr;73(3):308-22. Review.

PMID:
11345196
9.

Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.

Valent P, Deininger M.

Leuk Lymphoma. 2008 Apr;49(4):604-9. doi: 10.1080/10428190801923212. Review.

PMID:
18398718
10.

[Diversity of BCR and ABL gene breakpoints in chronic myelogenous leukemia].

Sugimoto T.

Rinsho Ketsueki. 2003 Feb;44(2):61-4. Review. Japanese. No abstract available.

PMID:
12692976
11.

Chronic myelogenous leukemia: molecular and cellular aspects.

Pasternak G, Hochhaus A, Schultheis B, Hehlmann R.

J Cancer Res Clin Oncol. 1998;124(12):643-60. Review.

PMID:
9879825
12.

[New approach in the diagnosis and monitoring of treatment in chronic myelogenous leukemia].

Matolcsy A.

Orv Hetil. 2004 Dec 26;145(52):2603-9. Review. Hungarian.

PMID:
15724695
13.
14.

BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts.

Skorski T.

Leuk Lymphoma. 2008 Apr;49(4):610-4. doi: 10.1080/03093640701859089. Review.

PMID:
18398719
15.

Does long-term culture favor normal clonogenic cells from interferon-treated patients with chronic myelogenous leukemia?

Pasternak G, Schultheis B, Heissig B, Hörner S, Sick C, Hehlmann R.

Leukemia. 1999 Apr;13 Suppl 1:S55-64. Review.

PMID:
10232367
16.

Chronic myelogenous leukemia: mechanisms underlying disease progression.

Shet AS, Jahagirdar BN, Verfaillie CM.

Leukemia. 2002 Aug;16(8):1402-11. Review.

17.

Characterization of cancer stem cells in chronic myeloid leukaemia.

Jørgensen HG, Holyoake TL.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1347-51. Review.

PMID:
17956348
18.
19.

New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.

Stefanachi A, Leonetti F, Nicolotti O, Catto M, Pisani L, Cellamare S, Altomare C, Carotti A.

Curr Cancer Drug Targets. 2012 Jun;12(5):571-96. Review.

PMID:
22414010
20.

[Molecular pathogenesis of chronic myeloid leukemia].

Sasaki K, Mitani K.

Nihon Rinsho. 2009 Oct;67(10):1894-9. Review. Japanese.

PMID:
19860186
Items per page

Supplemental Content

Write to the Help Desk